BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended | Dolla ...

Core Viewpoint - Azenta, Inc. is set to announce its fiscal first quarter 2026 earnings on February 4, 2026, before market opening, indicating a focus on financial performance and transparency [1]. Group 1: Financial Results Announcement - The earnings announcement will be followed by a conference call and live webcast on the same day at 8:30 a.m. Eastern Time, allowing analysts, investors, and media to engage with the company's financial results [2]. - A replay of the conference call will be available starting at 8:30 a.m. ET on February 5, 2026, ensuring accessibility for stakeholders who cannot attend the live event [2]. Group 2: Company Overview - Azenta, Inc. is recognized as a leading provider of life sciences solutions globally, facilitating faster market entry for impactful breakthroughs and therapies [3]. - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, catering to drug development, clinical research, and advanced cell therapies for top pharmaceutical, biotech, academic, and healthcare institutions [3]. - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey, showcasing its diverse service offerings [3]. - The company is headquartered in Burlington, MA, with operational presence in North America, Europe, and Asia, highlighting its global reach [4].

Core Viewpoint - Azenta, Inc. has announced a share repurchase program to buy back up to $250 million of its common stock, aimed at enhancing shareholder value and addressing perceived undervaluation [1][2]. Group 1: Share Repurchase Program - The share repurchase program allows Azenta to repurchase shares through various methods, including open market transactions and privately negotiated deals, subject to market conditions and legal requirements [1][2]. - The program commenced on December 9, 2025, and is set to continue until December 31, 2028, unless modified or terminated earlier by the Board [2]. Group 2: Capital Allocation Strategy - The company's capital allocation strategy focuses on four key areas: improving productivity and gross margins, accelerating organic growth, pursuing strategic mergers and acquisitions, and returning capital to shareholders through share repurchases [3]. - The share repurchase authorization is part of a deliberate strategy to enhance long-term shareholder value while maintaining flexibility for growth investments [3]. Group 3: Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [5]. - The company operates in North America, Europe, and Asia, and is headquartered in Burlington, Massachusetts [6].

Core Viewpoint - Azenta, Inc. will announce its fiscal fourth quarter and full year 2025 earnings on November 21, 2025, before market opens [1]. Financial Results Announcement - The company will host a conference call and live webcast to discuss its financial results on the same day at 8:30 a.m. Eastern Time, accessible via the Azenta website [2]. - A replay of the conference call will be available starting at 8:30 a.m. ET on November 22, 2025 [2]. Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, facilitating breakthroughs and therapies to market faster [3]. - The company offers a comprehensive suite of cold-chain sample management solutions and multiomics services, serving top pharmaceutical, biotech, academic, and healthcare institutions globally [3]. - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3]. Operational Footprint - Azenta is headquartered in Burlington, MA, with operations across North America, Europe, and Asia [4]. Upcoming Events - The company will host an Investor Day at its biorepository facility in Indianapolis, Indiana, on December 10, 2025 [5].

Core Insights - Azenta, Inc. has formed a strategic partnership with the PRECEDE Foundation to enhance early detection and prevention of pancreatic cancer [1][4] - The partnership aims to improve the five-year survival rate of pancreatic cancer from 13% to 50% within the next decade [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [8] - The company operates in North America, Europe, and Asia, with its headquarters in Burlington, Massachusetts [9] Industry Context - Pancreatic cancer is the third-leading cause of cancer-related deaths in the U.S., with over 66,500 diagnoses annually and a five-year survival rate of only 13% [2] - The PRECEDE Consortium, which includes over 60 academic medical centers, focuses on improving screening and risk modeling for individuals at hereditary risk of pancreatic cancer [3][6] Partnership Details - Azenta will provide secure storage for study samples in its biorepository, allowing PRECEDE researchers to concentrate on advancing diagnostics and patient survival [1][4] - The collaboration emphasizes Azenta's role in supporting high-impact life science research and enhancing the capabilities of biorepositories [4]

Core Viewpoint - Azenta, Inc. reported its financial results for the third quarter of fiscal 2025, showing a flat revenue year-over-year and a significant net loss due to discontinued operations and impairment charges. Financial Performance - Revenue from continuing operations was $144 million, unchanged from the previous year, with organic revenue declining by 2% year-over-year [3][8] - Sample Management Solutions revenue was $78 million, down 4% year-over-year, while Multiomics revenue increased to $66 million, up 4% year-over-year [3][8] - Diluted EPS from continuing operations was $0.01 compared to ($0.00) in the same quarter of the previous year, while total diluted EPS was ($1.15), a decrease of 30% from ($0.12) [3][8] - Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 12.3%, reflecting a 260 basis point improvement year-over-year [3][14] Management Commentary - The President and CEO, John Marotta, stated that significant organizational changes are underway, and the operational turnaround is progressing as planned, with a focus on cost management and execution [4][8] Cash and Liquidity - As of June 30, 2025, the company had a total balance of cash, cash equivalents, restricted cash, and marketable securities amounting to $565 million [14] - Operating cash flow for the quarter was $26 million, with capital expenditures of $11 million, resulting in free cash flow of $15 million [14] Guidance - Azenta reiterated its guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% relative to fiscal 2024 and an adjusted EBITDA margin expansion of approximately 300 basis points [14][8]

Company Overview - Azenta, Inc. is a leading provider of life sciences solutions globally, facilitating the faster market introduction of impactful breakthroughs and therapies [2] - The company offers a comprehensive suite of reliable cold-chain sample management solutions and multiomics services, catering to drug development, clinical research, and advanced cell therapies [2] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [2] Conference Participation - Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025 [1]

Company Overview - Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions globally, facilitating faster market access for impactful breakthroughs and therapies [3] - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, focusing on drug development, clinical research, and advanced cell therapies [3] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3] Upcoming Financial Announcement - Azenta will announce its fiscal third quarter 2025 earnings on August 5, 2025, before the market opens [1] - A conference call and live webcast to discuss the financial results will take place on the same day at 8:30 a.m. Eastern Time [2] - Analysts, investors, and media can access the live webcast through the Azenta website, with a replay available starting August 6, 2025, at 8:30 a.m. ET [2] Company Operations - Azenta is headquartered in Burlington, MA, and has operations across North America, Europe, and Asia [4]